Furosemide Market Size will Observe Lucrative Surge by the End 2027

Furosemide Market - Introduction

Furosemide is a medication used to reduce edema (extra fluid in the body) due to diseases/conditions such as kidney disease, heart disease, and liver disease. It is also used for the treatment of high blood pressure. Furosemide is sulfamoylanthranilic acid derivative. It is also known as diuretic and is primarily administered orally or intravenously. The injectable or intravenous form is used when the drug cannot be administered orally, especially in patients with chronic diseases. The medication helps the kidneys eliminate unneeded water and salt from the body through urine. It blocks the absorption of sodium, chloride, and water from the fluid in the kidneys. However, furosemide carries many side effects such as dehydration, low blood pressure, and electrolyte depletion. The medication reduces symptoms such as shortness of breath, and swelling of arms, legs, and abdomen.

Report Overview @ https://www.transparencymarketresearch.com/furosemide-market.html

Furosemide Market - Competitive Landscape

Key players operating in the global furosemide market are Sanofi, Pfizer Inc., Mylan N.V., Emcure Pharmaceuticals, Sun Pharmaceutical Industries Ltd., SteriMax, and Sandoz Canada Inc.

Mylan N.V.

Mylan N.V. is a pharmaceutical company offering generic and branded medications and serves regions including North America, Europe and Rest of World. The company operates in 140 countries across the globe. The company offers furosemide tablets indicated in adults and pediatric patients for the treatment of edema associated with cirrhosis of the liver, congestive heart failure and renal disease.

Get a Glimpse of the In-Depth Analysis through our Comprehensive "Furosemide Market" Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68165

Pfizer Inc

Pfizer is a global pharmaceutical company manufacturing includes medicines and vaccines and consumer health care products. The company leading supplier of high-quality, difficult-to-manufacture, injectable pharmaceutical and surgical products. Pfizer Inc. offers furosemide injection, solution indicated as adjunctive therapy in acute pulmonary edema and for for the treatment of edema.

Sanofi

Sanofi is a pharmaceutical company engaged in the development, production, and sale of pharmaceuticals and health care products for diabetes, cardiovascular, central nervous system, thrombosis, internal medicine, vaccines, and oncology. Sanofi offers LASIX, furosemide oral solution.

Furosemide Market - Dynamics

Furosemide is indicated for the treatment of edema associated with congestive heart failure, chronic renal failure & other diseases. Rise in prevalence of chronic diseases, increase in number of generic drug manufacturers for furosemide, and growth in number of surgical procedures are expected to drive the furosemide market during the forecast period. Additionally, increase in number of promising drugs in pipeline is anticipated to boost the market during the forecast period

Pre Book "Furosemide Market" Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=68165<ype=S

Increase in prevalence of chronic disease

The prevalence of chronic diseases such as heart failure and renal diseases is increasing across the globe. As per the Centre for Disease Control and Prevention (CDC), in the U.S., nearly 5.7 million adults had heart failure in 2016 and half of people with heart failure die within 5 years of diagnosis. According to Emory Healthcare, in the U.S., 550,000 new cases are diagnosed each year. Diabetes and obesity key contributors to rising number of patients with heart failure

Chronic kidney disease is another major health problem. More than 661,000 Americans have kidney failure. According to National Institute of Diabetes and Digestive and Kidney Diseases, more than 661,000 Americans have kidney failure, out of which 468,000 patients are on dialysis, and 193,000 patient live with a functioning kidney transplant. Nearly 47,000 Americans died from kidney disease in 2013.

Expanding operations in future? To get the perfect launch ask for a custom report here

Product recalls to restrain market growth

Voluntary product recall by pharmaceutical companies, and Food and Drug Administration (FDA) and other regulatory authorities is estimated to restrain the market. For instance, in February 2017, Roxane Laboratories Inc recalled 6493 bottles of Furosemide Tablets USP, 20 mg, available with prescription after a complaint about an unusually thick tablet. In October 2015, the company recalled 16,270 bottles of tablets of diuretic furosemide as per the FDA Enforcement Report. The recall was initiated, as the tablets were manufactured using Active Pharmaceutical Ingredient (API) intended for the oral-suspension version of the drug.

Furosemide market dominated by North America

North America is projected to account for the major share of the market in the near future owing to the increase in number of specialty care services for cardiac and kidney patients, and rise in demand for furosemide in health care institutes. Furthermore, rise in availability of medications for chronic disease/conditions in these pharmacies, ease of accessibility, and growth in chain of retail pharmacies supplying medications for furosemide are other key factors likely to support the growth of the market in North America

Asia Pacific market to grow at rapid pace

The market in Asia Pacific is estimated to expand at a faster pace than that in other regions during the forecast period, led by the increase in awareness about management of pulmonary edema among cardiac patients, rise in prevalence of cardiac diseases, and high demand for drugs in ambulatory surgical centers. Additionally, the increase in number of surgical centers and voluntary organizations conducting workshops & programs, rise in focus on adopting strategies for preventive care are likely to boost the growth of the market in the region.

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.